Primary Sclerosing Cholangitis (PSC) Market

Future Market Insights

Key Insight

The primary sclerosing cholangitis (PSC) market is projected to grow from USD 174.9 million in 2025 to USD 363.9 million by 2035, at a CAGR of 7.6%. BTT1023 will dominate with a 18.5% market share, while will lead the segment with a 0.0% share.

August 18, 2025

Anurag Sharma

287 Pages

Cite this Report

Primary Sclerosing Cholangitis (PSC) Market

https://www.futuremarketinsights.com/reports/primary-sclerosing-cholangitis-psc-market

License

Starting at US$ 5000

Buy Now

Summary ToC Companies

Key Players

Allergan plc
Durect Corporation
Falk Pharma GmbH
Takeda Pharmaceutical Company Limited

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Primary Sclerosing Cholangitis (PSC) Market

Key Players

Similar Industry Reports